Skip to main content
Publications
Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.
Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089